180 related articles for article (PubMed ID: 16703592)
1. Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001.
Sengupta S; Slezak JM; Blute ML; Leibovich BC; Sebo TJ; Myers RP; Cheville JC; Bergstralh EJ; Zincke H
Cancer; 2006 Jun; 106(12):2630-5. PubMed ID: 16703592
[TBL] [Abstract][Full Text] [Related]
2. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
[TBL] [Abstract][Full Text] [Related]
3. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer.
Burdick MJ; Reddy CA; Ulchaker J; Angermeier K; Altman A; Chehade N; Mahadevan A; Kupelian PA; Klein EA; Ciezki JP
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1439-45. PubMed ID: 18963536
[TBL] [Abstract][Full Text] [Related]
4. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival.
Turker P; Bas E; Bozkurt S; Günlüsoy B; Sezgin A; Postacı H; Turkeri L
Urol Oncol; 2013 Jan; 31(1):93-8. PubMed ID: 21316989
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma.
Rasiah KK; Stricker PD; Haynes AM; Delprado W; Turner JJ; Golovsky D; Brenner PC; Kooner R; O'Neill GF; Grygiel JJ; Sutherland RL; Henshall SM
Cancer; 2003 Dec; 98(12):2560-5. PubMed ID: 14669274
[TBL] [Abstract][Full Text] [Related]
6. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens.
Whittemore DE; Hick EJ; Carter MR; Moul JW; Miranda-Sousa AJ; Sexton WJ
J Urol; 2008 Feb; 179(2):516-22; discussion 522. PubMed ID: 18076949
[TBL] [Abstract][Full Text] [Related]
7. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival.
Tollefson MK; Leibovich BC; Slezak JM; Zincke H; Blute ML
J Urol; 2006 Feb; 175(2):547-51. PubMed ID: 16406993
[TBL] [Abstract][Full Text] [Related]
8. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML
BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer grading: the effect of stratification of needle biopsy Gleason Score 4 + 3 as high or intermediate grade.
Fanning DM; Kay E; Fan Y; Fitzpatrick JM; Watson RW
BJU Int; 2010 Mar; 105(5):631-5. PubMed ID: 19732053
[TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
11. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
12. Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients.
Vira MA; Tomaszewski JE; Hwang WT; D'Amico AV; Whittington R; Vanarsdalen K; Wein AJ; Malkowicz SB
Urology; 2005 Nov; 66(5):1015-9. PubMed ID: 16286115
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy.
Müntener M; Epstein JI; Hernandez DJ; Gonzalgo ML; Mangold L; Humphreys E; Walsh PC; Partin AW; Nielsen ME
Eur Urol; 2008 Apr; 53(4):767-75; discussion 775-6. PubMed ID: 18060681
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate.
Arora R; Koch MO; Eble JN; Ulbright TM; Li L; Cheng L
Cancer; 2004 Jun; 100(11):2362-6. PubMed ID: 15160339
[TBL] [Abstract][Full Text] [Related]
15. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
16. High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy.
Pierorazio PM; Lambert SM; Matsukhani M; Sprenkle PC; McCann TR; Katz AE; Olsson CA; Benson MC; McKiernan JM
BJU Int; 2007 Nov; 100(5):1066-70. PubMed ID: 17784880
[TBL] [Abstract][Full Text] [Related]
17. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
18. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era.
Desireddi NV; Roehl KA; Loeb S; Yu X; Griffin CR; Kundu SK; Han M; Catalona WJ
Urology; 2007 Nov; 70(5):950-5. PubMed ID: 18068453
[TBL] [Abstract][Full Text] [Related]
19. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
